“…The presence of CD163 + macrophages was suggested to have a stronger association with less favorable clinicopathological features than CD68 + macrophages (Medrek, Ponten, Jirstrom, & Leandersson, 2012). Numerous studies demonstrate that elevated CD163 expression correlates with advanced cancer stages, unfavorable prognosis, early distant recurrence, and reduced patient survival in various types of cancer, which include melanoma (Jensen et al, 2009), meningioma (Kanno et al, 2013), breast cancer (Mansfield, Heikkila, von Smitten, Vakkila, & Leidenius, 2012; Shabo, Stal, Olsson, Dore, & Svanvik, 2008; Tiainen et al, 2014), colorectal cancer (Edin et al, 2012; Shabo, Olsson, Elkarim, Sun, & Svanvik, 2014), oral squamous cell carcinoma (He, Bao, et al, 2014; Wang et al, 2014), ovarian carcinoma (Reinartz et al, 2014), HCC (Kong et al, 2013), angiosarcoma (Fujimura et al, 2013), glioma (Komohara et al, 2008), and gastrointestinal stromal tumors (van Dongen et al, 2010), and hematopoietic malignancies, such as T cell leukemia/lymphoma (Komohara et al, 2013), acute myeloid leukemia (Garcia, Gardner, & Reichard, 2008), and classical Hodgkin lymphoma (Klein et al, 2014; Koh, Park, Yoon, Suh, & Huh, 2014). A recent study showed that relapse of head and neck cancer after chemoradiotherapy also correlated with CD163 + macrophages in primary tumor and CD11b + myeloid cells in recurrences (Balermpas et al, 2014).…”